Delirium and Opioids in Terminal Cancer

Pierre R. Gagnon, MD, FRCPC^{1,4}, Pierre Allard, MD, FRCPC, PhD³, Bruno Gagnon, MD, MSc², Chantal Merette, PhD⁴, François Tardif, MSc¹, Claudia Emond, MSc⁴ and Valérie Jomphe, MSc⁴

¹Laval University, Faculty of Pharmacy; Hôtel-Dieu de Québec Research Center (CHUQ); Maison Michel-Sarrazin, Quebec, QC; ²Palliative Care, McGill University, Montreal, QC ³Palliative care, Elizabeth Bruyere Hospital, Ottawa, ON; ⁴Laval University, Robert Giffard Research Center, Quebec, QC, Canada





Background

Oblight Deligities a severe and frequent complication in terminal cancer

Opioid intake is among the most well known delirium risk factor in terminal

Methods

1516 patients in 7 palliative care units in Canada, who survived longer than 48 hours, were followed prospectively from October 2001 to January 2005 from admission until patient's death

Objective

To correlate the use of opioids before and after the occurrence of significant delirium symptoms in terminal cancer

- The Confusion Rating Scale (CRS) was used for delirium screening and monitoring
- Daily equivalent of opioids (morphine SC) was used for analysis

Results


3 T

2,5-

Table 1. Socio-demographic data of patients

Characteristics	Delirium-free patients; n=815	Delirious patients; n=701	p value
Age (year)	68,3 (±13)	68,6 (±13)	NS
Length of stay/survival (days)	16,0 (±15,4)	26,6 (±20,3)	< 0,001
Gender (% of women)	54,7%	52,6%	NS
At least 50% of time confined to bed (ECOG 3-4)	88,8%	86,9%	< 0,001

Figure 1. Mean daily doses of opioids before and after significant delirium symptoms were observed (Day 0)



Primary site

Trachea, bronchus, lungs	189 (23,2%)	183 (26.1%)	NS
Digestive track	140 (17,2%)	126 (18,0%)	NS
Colon & rectum	110 (13,5%)	101 (14.4%)	NS
Genital and urinary tract	105 (12,9%)	89 (12,7%)	NS
Breast	79 (9,7%)	67 (9,6%)	NS
Prostate	37 (4,5%)	18 (2,6%)	0,04
Others	155 (19,0%)	117 (16,7%)	NS
Past history of delirium			
Yes	87 (10,7%)	126 (18,0%)	< 0,001
None	440 (54,0%)	339 (48,4%)	< 0,001
Unknown	288 (35,3%)	236 (33,7%)	NS

Table 2. Association between Opioid intake and Delirium


Delirious

Delirium-free population

Odd Ratio (p value)

Figure 2. Average CRS score obtained before and after significant delirium symptoms were observed (Day 0)

2,31




Conclusions

Opioids were associated with delirium

There is a direct relation between high opioid doses and occurence of delirium

Analysis of delirium risk factors in terminal cancer remains a complex and challenging task



References

1. Gaudreau, J.D., Gagnon, P., Harel, F., Roy, M.A., Tremblay, A. 2005. Psychoactive medications and risk of delirium in hospitalized cancer patients. J Clin Oncol. Sep; 23(27): 6712-8. 2. Gaudreau, J.D., Gagnon, P., Roy, M.A., Harel, F., Tremblay, A. 2005. Association between psychoactive medications and delirium in hospitalized patients: a critical review. Psychosomatics. 46(4): 302-16.

Supported by funding from The National Cancer Institute of Canada with funds from the Canadian Cancer Society (Grant no. 14371).